SCHEMBL6041697

SCHEMBL6041697

CSc1ccc(COC2CN(C(=O)O)CCC2c2ccc(F)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM1A O60341 1/20 0.39
MAOB P27338 1/20 0.39
GPR119 Q8TDV5 1/20 0.37
CCR3 P51677 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
LIPG Q9Y5X9 1/20 0.36
S1PR5 Q9H228 1/20 0.36
KCNH2 Q12809 1/20 0.36
F10 P00742 1/20 0.35
PTGER1 P34995 1/20 0.35
ALDH1A1 P00352 1/20 0.35
ALOX5 P09917 1/20 0.35
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6042876 0.92 GPR119 (0.38) MEN1KMT2AGPR119SMN1; SMN2KCNH2
SCHEMBL6952362 0.87 MEN1 (0.39) MEN1KMT2AKDM1AMAOBCCR3
SCHEMBL6042033 0.87 REN (0.45) MEN1KMT2AKDM1AMAOBSMN1; SMN2
SCHEMBL6041755 0.85 KDM1A (0.38) KDM1AMAOBSMN1; SMN2LIPGS1PR5
SCHEMBL6042402 0.85 GPBAR1 (0.44) KDM1AMAOBGPR119CCR3
SCHEMBL6043843 0.84 SLC6A2 (0.39) KDM1AMAOBSMN1; SMN2POLB
SCHEMBL6949602 0.81 GPR119 (0.39) MEN1KMT2AKDM1AMAOBGPR119
SCHEMBL6042313 0.81 RXRB (0.39) KDM1AMAOBSMN1; SMN2LIPGALDH1A1
SCHEMBL6041769 0.81 REN (0.42)
SCHEMBL6043496 0.81 REN (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
EP-0863875-B1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY HOFFMANN LA ROCHE (CH) 2003-06-04 EP disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 MEN1 2561/4885KMT2A 2702/4885KDM1A 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.